Endocrine Abstracts

Background: The incidence of young-onset colorectal adenocarcinoma is predicted to continue rising over the next decade. Overall, data about young onset neuroendocrine tumors (NET) is scarce. In this analysis, we sought to investigate trends and differences in survival for colorectal NET in the young-onset population and to compare this with the average onset population. In addition, we seek to compare differences between adenocarcinoma and NET in the young-onset population. <...

Background: Metastatic neuroendocrine carcinomas (NECs) have a poor prognosis, and standard first-line chemotherapy combines etoposide (E) and platinum (P) has limited benefit. Currently, there is no standard second-line therapy. Irinotecan-based regimens have shown benefits; hence we explored nanoliposomal Irinotecan (nal-IRI) efficacy in this patient population.Methods: In this open-label, single-arm, multi-center Phase 2 study, advanced GEP or unknown...